| HOME >> BIOLOGY >> TECHNOLOGY |
PRINCETON, N.J., July 16 /PRNewswire-FirstCall/ -- BioWa, Inc. and Medarex, Inc. (Nasdaq: MEDX) announced today that they have entered into a license agreement which provides Medarex with the first ever access to BioWa's COMPLEGENT(TM) Technology for enhancing the complement-dependent cytotoxicity (CDC) of select Medarex therapeutic antibodies.
The license grants Medarex non-exclusive rights to research, develop and commercialize therapeutic antibodies based on COMPLEGENT(TM) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payment, license fees, development milestone payments and royalties on products. Other details of the agreement are not disclosed.
"We are very pleased to announce this new partnership with Medarex, who is also our first partner for POTELLIGENT(R) Technology," commented Dr. Masamichi Koike, President and CEO of BioWa. "This collaboration with Medarex greatly helps us explore the potential of COMPLEGENT(TM) Technology for antibody-based therapies."
"We are excited about the possibility of enhancing our antibodies with BioWa's technology platform," said Howard H. Pien, President and CEO of Medarex. "Our partnership grants Medarex the first access to COMPLEGENT(TM) Technology and we look forward to investigating its potential as we continue to advance our pipeline."
About COMPLEGENT(TM) Technology
COMPLEGENT(TM) Technology is a new technology developed by Kyowa Hakko
Kogyo Co., Ltd. that enhances one of the major mechanisms of action of an
antibody, CDC. With an approach called isotype chimerism, in which portions
of IgG3, an antibody's isotype, are introduced into corresponding regions
of IgG1, the standard isotype for therapeutic antibodies, COMPLE
'/>"/>
| SOURCE Medarex, Inc. Copyright©2008 PR Newswire. All rights reserved |